FDA Rejects Merck's Treatment for Bone Cancer

Dow Jones Newswires (06/05/12) Stynes, Tess
The U.S. Food and Drug Administration has rejected a new drug application from Merck for an investigational maintenance treatment for patients with metastatic soft tissue or bone sarcoma. The agency said further clinical trials of the treatment—ridaforolimus—would be needed to assess its effectiveness and safety—before any potential approval. Merck said it is in continuing talks with health regulators in Europe and other countries regarding ridaforolimus and is studying the treatment in "combination with other mechanisms in several tumor types."

Read the complete article


Share |

Sponsor Highlights

inPharmacyJobs